Patents by Inventor Guo-jie Ye

Guo-jie Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250121092
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Application
    Filed: May 7, 2024
    Publication date: April 17, 2025
    Inventor: Guo-jie Ye
  • Publication number: 20210171591
    Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.
    Type: Application
    Filed: September 9, 2020
    Publication date: June 10, 2021
    Inventors: Guo-jie Ye, Jilin Liu
  • Publication number: 20210154325
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Application
    Filed: December 1, 2020
    Publication date: May 27, 2021
    Inventor: Guo-jie Ye
  • Publication number: 20190276507
    Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.
    Type: Application
    Filed: October 22, 2018
    Publication date: September 12, 2019
    Inventors: Guo-jie Ye, Jilin Liu
  • Publication number: 20190002913
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Application
    Filed: April 23, 2018
    Publication date: January 3, 2019
    Inventors: Guo-jie Ye, Jeffrey D. Chulay
  • Publication number: 20180154022
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Application
    Filed: June 29, 2017
    Publication date: June 7, 2018
    Inventor: Guo-Jie Ye
  • Patent number: 9982275
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 29, 2018
    Assignee: Applied Genetic Technologies Corporation
    Inventors: Guo-Jie Ye, Jeffrey D. Chulay
  • Patent number: 9724429
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: August 8, 2017
    Assignee: Applied Genetic Technologies Corporation
    Inventor: Guo-Jie Ye
  • Publication number: 20170166617
    Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.
    Type: Application
    Filed: November 23, 2016
    Publication date: June 15, 2017
    Applicant: Applied Genetic Technologies Corporation
    Inventors: Guo-Jie Ye, Jilin Liu
  • Patent number: 9534225
    Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: January 3, 2017
    Assignee: Applied Genetic Technologies Corporation
    Inventors: Guo-Jie Ye, Jilin Liu
  • Publication number: 20150353938
    Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.
    Type: Application
    Filed: April 15, 2015
    Publication date: December 10, 2015
    Applicant: APPLIED GENETIC TECHNOLOGIES CORPORATION
    Inventors: Guo-Jie Ye, Jilin Liu
  • Publication number: 20140364486
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Application
    Filed: May 5, 2014
    Publication date: December 11, 2014
    Inventor: Guo-Jie Ye
  • Publication number: 20130317091
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
    Type: Application
    Filed: July 8, 2013
    Publication date: November 28, 2013
    Inventors: Guo-Jie Ye, Jeffrey D. Chulay
  • Patent number: 6120993
    Abstract: The present invention is directed to isolated nucleic acid molecules encoding mammalian 5-oxoprolinase (m 5-OPase). Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for increasing or decreasing the expression of m 5-OPase in host cells. The invention further provides a method of screening a substance for the ability of the substance to modify m 5-OPase function, and a method for isolating other m 5-OPase molecules. DNA oligomers and antibodies specific for m 5-OPase are provided, each of which can be used to detect m 5-OPase in a sample.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: September 19, 2000
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Guo-jie Ye, Esther Breslow, Alton Meister, deceased, by Kenneth Meister, executor